These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33402343)

  • 1. Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland.
    Bjornsson AH; Grondal G; Kristjansson M; Jonsdottir T; Love TJ; Gudbjornsson B;
    Ann Rheum Dis; 2021 May; 80(5):671-672. PubMed ID: 33402343
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini
    Monti S; Montecucco C
    Ann Rheum Dis; 2021 Feb; 80(2):e15. PubMed ID: 32414805
    [No Abstract]   [Full Text] [Related]  

  • 3. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.
    Michelena X; Borrell H; López-Corbeto M; López-Lasanta M; Moreno E; Pascual-Pastor M; Erra A; Serrat M; Espartal E; Antón S; Añez GA; Caparrós-Ruiz R; Pluma A; Trallero-Araguás E; Barceló-Bru M; Almirall M; De Agustín JJ; Lladós J; Julià A; Marsal S
    Semin Arthritis Rheum; 2020 Aug; 50(4):564-570. PubMed ID: 32425260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
    Sanchez-Piedra C; Diaz-Torne C; Manero J; Pego-Reigosa JM; Rúa-Figueroa Í; Gonzalez-Gay MA; Gomez-Reino J; Alvaro-Gracia JM;
    Ann Rheum Dis; 2020 Jul; 79(7):988-990. PubMed ID: 32503857
    [No Abstract]   [Full Text] [Related]  

  • 5. What is the true incidence of COVID-19 in patients with rheumatic diseases?
    Favalli EG; Ingegnoli F; Cimaz R; Caporali R
    Ann Rheum Dis; 2021 Feb; 80(2):e18. PubMed ID: 32321723
    [No Abstract]   [Full Text] [Related]  

  • 6. COVID-19 epidemiology in rheumatic diseases in Tuscany: A case-control study.
    Francesconi P; Cantini F; Profili F; Mannoni A; Bellini B; Benucci M
    Joint Bone Spine; 2021 May; 88(3):105131. PubMed ID: 33486110
    [No Abstract]   [Full Text] [Related]  

  • 7. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
    Hasseli R; Mueller-Ladner U; Schmeiser T; Hoyer BF; Krause A; Lorenz HM; Regierer AC; Richter JG; Strangfeld A; Voll RE; Pfeil A; Schulze-Koops H; Specker C
    RMD Open; 2020 Sep; 6(2):. PubMed ID: 32878994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency and severity of COVID-19 in patients treated with biological disease-modifying anti-rheumatic drugs for inflammatory rheumatic disease: a cross-sectional study.
    Lohse A; Bossert M; Bozgan AM; Charpentier A; Guillochon C; Bourgoin C; Balblanc JC; Conrozier T
    Clin Exp Rheumatol; 2020; 38(6):1273. PubMed ID: 33253100
    [No Abstract]   [Full Text] [Related]  

  • 9. Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark.
    Cordtz R; Lindhardsen J; Soussi BG; Vela J; Uhrenholt L; Westermann R; Kristensen S; Nielsen H; Torp-Pedersen C; Dreyer L
    Rheumatology (Oxford); 2021 Oct; 60(SI):SI59-SI67. PubMed ID: 33369663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of Covid-19 in patients with rheumatic diseases and the effects of the pandemic on rheumatology outpatient care: A single-centre experience from Turkey.
    Batıbay S; Koçak Ulucaköy R; Özdemir B; Günendi Z; Göğüş FN
    Int J Clin Pract; 2021 Sep; 75(9):e14442. PubMed ID: 34105856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs.
    Conticini E; Bargagli E; Bardelli M; Rana GD; Baldi C; Cameli P; Gentileschi S; Bennett D; Falsetti P; Lanzarone N; Bellisai F; Barreca C; D'Alessandro R; Cantarini L; Frediani B
    Ann Rheum Dis; 2021 Feb; 80(2):e14. PubMed ID: 32414804
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases.
    Cook C; Patel NJ; D'Silva KM; Hsu TY; DiIorio M; Prisco L; Martin LW; Vanni K; Zaccardelli A; Todd D; Sparks JA; Wallace ZS
    Ann Rheum Dis; 2022 Feb; 81(2):289-291. PubMed ID: 34489304
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy.
    Quartuccio L; Valent F; Pasut E; Tascini C; De Vita S
    Joint Bone Spine; 2020 Oct; 87(5):439-443. PubMed ID: 32445935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19: a primer for the rheumatologist: management of patients and care settings.
    Calabrese C; Lehman B
    Curr Opin Rheumatol; 2020 Sep; 32(5):429-433. PubMed ID: 32744823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate is the leading DMARD in Finland.
    Klaukka T; Kaarela K
    Ann Rheum Dis; 2003 May; 62(5):494; author reply 494-5. PubMed ID: 12695174
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases.
    Friedman MA; Curtis JR; Winthrop KL
    Ann Rheum Dis; 2021 Oct; 80(10):1255-1265. PubMed ID: 34493491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient.
    Sagnelli C; Gentile V; Tirri R; Macera M; Cappabianca S; Ciccia F; Coppola N;
    J Infect; 2020 Dec; 81(6):979-997. PubMed ID: 32474034
    [No Abstract]   [Full Text] [Related]  

  • 18. COVID-19 in patients with rheumatological diseases treated with anti-TNF.
    Brito CA; Paiva JG; Pimentel FN; Guimarães RS; Moreira MR
    Ann Rheum Dis; 2021 May; 80(5):e62. PubMed ID: 32546603
    [No Abstract]   [Full Text] [Related]  

  • 19. Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?
    Favalli EG; Monti S; Ingegnoli F; Balduzzi S; Caporali R; Montecucco C
    Arthritis Rheumatol; 2020 Oct; 72(10):1600-1606. PubMed ID: 32506699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study.
    Sozeri B; Ulu K; Kaya-Akça U; Haslak F; Pac-Kisaarslan A; Otar-Yener G; Baba O; Altug-Gucenmez O; Sahin N; Bağlan E; Sönmez HE; Cakmak F; Ozturk K; Gezgin-Yıldırım D; Şener S; Barut K; Batu ED; Yıldız M; Basaran O; Adrovic A; Sahin S; Ozdel S; Bilginer Y; Poyrazoglu MH; Demir F; Yuksel S; Kalyoncu M; Kasapcopur O; Ozen S; Aktay-Ayaz N
    Rheumatol Int; 2022 Mar; 42(3):469-475. PubMed ID: 34570263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.